Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer

Fig. 2

Antitumor activity of SHR-1701 in combination with bevacizumab and XELOX. Responses were assessed by investigator per RECIST V1.1. a Best change of target lesions from baseline in each patient. b Percentage change from baseline in target lesion tumor burden over time. c Survival time and duration of tumor response in 37 responders. The thick blue lines indicate the duration of survival follow-up. d Kaplan-Meier plot of PFS in all 62 patients. Crosses denote censored patients. PD, progressive disease; CR, complete response; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; NE, not evaluated. PFS, progression-free survival; CI, confidence interval

Back to article page